@article{cf4492363d60494ea7c3367a6fa9b36f,
title = "Clinical Outcome for Patients with Metastatic Colorectal Cancer (mCRC) Enrolled in Phase I Clinical Trials: Single Institution Experience.",
author = "Santiago Aparo and Shah, \{Umang H.\} and Gopichand Pendurti and Umang Swami and Yijuan Hou and Ghalib, \{Mohammad Haroon\} and Imran Chaudhary and Sridhar Mani and Sanjay Goel",
note = "e13550 Background: Phase I studies are a fundamental step in anti-cancer drug development. Prior meta-analysis looking at phase I studies showed an overall response rate (ORR) of 10.6 \% and grade 4 toxicity rate of 14.3 \%, and specifically, patients (pts) with mCRC enrolled in phase I trials had an ORR of 1.3 \%.",
year = "2013",
language = "American English",
volume = "31",
journal = "Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting",
}